NeuraVi

NeuraVi is an Australian neurotech startup developing closed-loop vagus nerve stimulation (VNS) devices designed to treat treatment-resistant depression and inflammatory disorders. The company's core technology leverages real-time biofeedback mechanisms to deliver intelligent, adaptive stimulation patterns rather than static treatment approaches. By combining neurophysiological monitoring with precision stimulation, NeuraVi aims to improve therapeutic efficacy while minimizing side effects associated with traditional open-loop neuromodulation devices.

Based in Melbourne, NeuraVi secured $4 million in seed funding to advance its technology platform toward clinical validation and regulatory approval. The company is positioned within a growing segment of the neuromodulation market that emphasizes personalized, intelligent stimulation protocols. This funding milestone reflects investor confidence in the company's approach to addressing the significant unmet need in treatment-resistant depression, a condition affecting millions globally with limited effective therapeutic options.

NeuraVi represents an important advancement in the neurotech industry by demonstrating how closed-loop systems and biofeedback integration can enhance traditional neuromodulation approaches. As the field moves toward more sophisticated, data-driven devices, the company's work contributes to establishing new standards for safety and efficacy in vagus nerve stimulation. Their focus on treatment-resistant depression also addresses a critical healthcare gap, potentially offering hope to patients who have exhausted conventional pharmaceutical and psychotherapeutic interventions.